Excellent point. It's with the moderate to severe group that leronlimab has been most impressive. The 65 (I think that's the right number.) patients who received leronlimab under the emergency indication were certainly not in the mild to moderate group. Getting people off respirators and heart/lung machines is what we hope to see with CD-12. As has been pointed out, people in the mild to moderate group can get better on their own. That isn't going to happen with the moderate to severe population.